HOME
>
臨床医学：内科
>
腎臓
> 透析療法ネクスト　VII　腎性貧血を再考する

透析療法ネクスト　VII　腎性貧血を再考する

出版社：	医学図書出版
著者：	秋葉隆・秋澤忠男／編
発行日：	2008-06-01
分野：	臨床医学：内科 > 腎臓
ISBN：	9784871513500
電子書籍版：	2008-06-01

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

2,860 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

腎性貧血管理は世界で、そして日本で大きな変化を遂げている。本特集により、目標Hbを含むガイドラインの変遷とそれを裏付けるエビデンス、そして新たなESAの実用化など、腎性貧血治療を巡る最新の進歩をご理解いただければ幸いである。

目次

透析療法ネクスト　VII　腎性貧血を再考する

―目次―

特集『腎性貧血を再考する』
　DOPPSからみた世界の腎性貧血治療
　わが国の腎性貧血治療ガイドラインの現状と課題
　世界の腎性貧血治療ガイドラインと
　　目標ヘモグロビン濃度をめるぐ課題
　Cardio-Renal Anemia(CRA) Syndrome
　腎性貧血と心血管合併症
　腎性貧血治療とQOL
　腎性貧血治療における鉄補充療法と問題点
　透析医療におけるヒューマンエラー対策の考え方
　　−低リスクシステム構築の条件とエラー対策の発想手順―
　ダルベポエチンαによる投与頻度の減少がもたらすメリット
　腎性貧血治療のクリニカルパス
　腹膜透析患者の腎性貧血治療
　ネスプの開発と特性　
　透析療法の歴史(7)―坑凝固薬の歴史―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.16 掲載の参考文献

1) Medical and Drug J 38 : 783, 2002

2) Hayashi T, Suzuki A, Shoji T, et al. : Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35 : 250, 2000

3) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease : Evaluation, Classification, and Stratification Am J Kidney Dis 39 (Suppl 1) : S170, 2002

4) Proc Natl Acad Sci USA 85 : 6142, 1988

5) 椿原美治, 林晃正, 勝二達也, 他 : 保存期慢性腎不全患者の残腎機能に及ぼす長期エリスロポエチン投与の効果. 腎不全 5 : 37, 1993

6) Kuriyama S, Tomonari H, Yoshida H, et al. : Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 : 176, 1997

7) Davis MD, Fisher MR, Gangnon RE, et al. : Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss : Early Treatment Diabetic Retinopathy Study Report#18, Invest Ophthalmol Vis Sci 39 : 233, 1998

8) Watanabe D, Suzuma K, Matsui S, et al. : Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. New Engl J Med 353 : 782, 2005

9) Kuriyama S, Hopp L, Yoshida H, et al. : Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 9 : 426, 1996

10) Movilli E, Pertica N Camerini C, et al. : Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 39 : 850, 2002

11) Saran R Brag9-Gresham JL, Rayner HC, et al. : Nonadherence in hemodialysis : associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64 : 254, 2003

12) Inagaki H, Kuroda M, Watanabe S, et al. : Changcs in major blood components after adopting the supine position during haemodialysis. Nephrol Dial Transplant 16 : 798-802, 2001

13) http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDApdf

14) Besarab A, Bolton WK, Browne JK, et al. : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339 : 584, 1998

特集『腎性貧血を再考する』

P.26 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況. 2005年12月31日現在. (社) 日本透析医学会, 東京, 2006.

2) Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Saito A, et al. : Association of Comorbid conditions and mortality in hemodialysis patients in Europe, Japan and the United States in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003 ; 14 : 3270-3277.

3) United States Renal Data System 2005 Renal Data Report

4) 三村信英 : リコンビナント・エリスロポエチンによる腎性貧血治療ガイドライン, 腎不全医療研究事業研究班報告書, 厚生省, 1991.

5) Pisoni RL, Bragg-Gresham JL, Young EW, et al. : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004 ; 44 : 94-111.

6) Locatelli F, Pisoni RL, Combe C, et al. : Anemia in hemodialysis patients of five European countries : Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004 ; 19 : 121-132.

7) Gejyo F, Saito A, Akizawa T, et al. : 2004 Japanese Society for Dialysis Therapy Guideline for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004 ; 8 : 443-459.

8) Inagaki H, Kuroda M, Watanabe S, et al. : Changes in major blood components after adopting the spine position during hemodialysis. Nephrol Dial Transplant 2001 ; 16 : 798-802.

9) Drueke TB, Locatelli F, Clyne N, et al. : Normalization of Hemoglobin Level in Patientswith Chronic Kidney Disease and Anemia. N Engl J Med 2006 ; 355 : 2071-2084.

10) Singh AK Szczech L, Kezhen L. Tang KL, et al. : Correction of Anemia with Epoetin Alfain Chronic Kidney Disease. N Engl J Med 2006 ; 355 : 2085-2098.

11) 未発表データ

P.41 掲載の参考文献

1) 2004年版日本透析医学会「慢性血液透析患者における腎性貧血治療のガイドライン」透析会誌 37 : 1737-1763, 2004.

2) Pisoni RL, Brag9-Gresham JL, Young EW, et al. : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004.

3) 日本透析医学会統計調査委員会編 : わが国の慢性透析療法の現況 (2005年12月31日現在), 日本透析医学会, 2006.

4) 日本透析医学会統計調査委員会編 : 慢性透析療法の現況 (2006年12月31日現在), 日本透析医学会, 2007.

5) Foley RN, Parfrey PS, Harnett JD : The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28 : 53-61, 1996.

6) Madore F, Lowrie EG, Brugnara C, et al. : Anemia in hemodialysis patients : variables affecting this outcome predictor. J Am Soc Nephrol 8 : 1921-1929, 1997.

7) Ma JZ, Ebben J, Xia H, et al. : Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10 : 610-619, 1999.

8) Collins AJ, Li S, St Peter W, et al. : Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12 : 2465-2473, 2001.

9) Ifudu O, Uribarri J, Rajwani I : Low hematocrit may connote a malnutrition/inflammation syndrome in hemodialysis patients. Dial Transplant 31 : 845-878, 2002.

10) Avram MM, Blaustein D, Fein PA, et al. : Hemoglobin predicts long-term survival in dialysis patients : A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl 87 : S6-S11, 2003.

11) Ofsthun N, Labrecque J, Lacson E, et al. : The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63 : 1908-1914, 2003.

12) Warady BA, Ho M : Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18 : 1055-1062, 2003.

13) Lowrie EG, Curtin RB, LePain N, et al. : Medical Outcomes Study Short Form-36 : Aconsistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 41 : 1286-1292, 2003.

14) Locatelli F, Pisoni RL, Combe C, et al. : Anaemia in haemodialysis patients of five European countries : Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 : 121-132, 2004.

15) Li S, Collins AJ : Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65 : 626-633, 2004.

16) Li S, Foley RN, Collins AJ : Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65 : 1864-1869, 2004.

17) Besarab A, Bolton WK Browne JK et al. : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584-590, 1998.

18) Furuland H, Linde T, Ahlmen J, et al. : A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 : 353-361, 2003.

19) Foley RN, Parfrey PS, Morgan J, et al. : Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 : 1325-1335, 2000.

20) Parfrey PS, Foley RN, WittreicHbH, et al. : Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 : 2180-2189, 2005.

21) Roger SD, McMahon LP, Clarkson A, et al. : Effects of early andLate intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4) : results of a randomized clinical trial. J Am Soc Nephrol 15 : 148-156, 2004.

22) Levin A, Djurdjev O, Thompson C, et al. : Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46 : 799-811, 2005.

23) Rossert J, Levin A, Roger SD, et al. : Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47 : 738-750, 2006.

24) Drueke TB, Locatelli F, Clyne N, et al. : CRE-ATE Investigators : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006.

25) Singh AK, Szczech L, Tang KL, et al. : CHOIR Investigators : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006.

26) Ritz E, Laville M, Bilous RW, et al. : Target level for hemoglobin correction in patients with diabetes and CKD : primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49 : 194-207, 2007.

27) Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300 : 573-578, 1990.

28) Moreno F, Sanz-Guajardo DLopez-Gomez JM, et al. : Increasing the hematocrit has a beneficial effect on quaiity of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11 : 335-342, 2000.

29) Foley RN. Do we know the correct hemoglobin target for anemic patients with chronic kidney disease? Clin J Am Soc Nephrol 1 : 678-684, 2006.

30) Levin A. Understanding recent haemoglobin trials in CKD : methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 22 : 309-312, 2007.

31) Phrommintikul A, Haas SJ, Elsik M, et al. : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis. Lancet 369 : 381-388, 2007.

32) Zhang Y, Thamer M, Stefanik K, Kaufman J, and Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 : 866-876, 2004.

33) Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 : 1337-1343, 2005.

34) Ebben JP, Gilbertson DT, Foley RN, and Collins AJ. Hemoglobin level variability : Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 : 1205-1210, 2006.

35) NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia in Chronic Kidney Disease : 2007 Update of Hemoglobin Target., Am J Kidney Dis, 50 : 471-530, 2007.

36) FDA ALERT [11/16/2006, Updated 2/16/2007 and 3/9/2007］ : Information for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)］<http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE_HCP.htm>

37) KDOQI ; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (Suppl 3) : S11-S145, 2006.

38) Locatelli F, Aljama P, Barany P, et al. : Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (Suppl 2) : ii1-47, 2004.

39) Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, lmai E, Hori M : Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure., Am J Kidney Dis, 35 : 250-256, 2000.

40) Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O : Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients., Nephron, 77 : 176, 1997.

41) Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S, and all the KRN321 AO9 Study Group : Darbepoetin alfa (KRN321) administered intravenously once monthly maintains Hb levels in peritoneal dialysis patients., Ther Apher Dial. (in press)

42) Kubota M, Hiramitsu M, Yamakawa M, Fukuhara S, Morita T, Akizawa T, and KRN321 Study Group : Target Level for Hemoglobin Correction by Darbepoetin Alfa (KRN321) for Peritoneal Dialysis (PD) Patients in Japan. Paper presented at : 2007 ASN Congress (SU-PO792), 2007.

43) Hirakata H, Gejyo F, Suzuki M, Saito A, Iino Y, Watanabe Y, Tsubakihara Y, Akizawa T, Koshikawa S : Effect of Darbepoetin Alfa (KRN321) subcutaneous treatment on hemoglobin levels, Health-Related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis. Paper presented at : 2006 ASN Congress (SA-PO204), 2006.

44) Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita T, Hiroe M, Hada Y, Tsubakihara Y, and KRN321 Study Group : Taget Level for Hemoglobin Correction by Darbepoetin Alfa (KRN321) for Patients with Chronic Kidney Disease (CKD) Not on Dialysis in Randomaized Controlled Study ; from the Viewpoint of the Efficacy. Paper presented at : 2007 ASN Congress (SU-PO804), 2007.

45) Tsubakihara Y, Shoji T, Gelyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita T, Hiroe M, Hada Y, Akizawa T, and KRN321 Study Group : Taget Level for Hemoglobin Correction by Darbepoetin Alfa (KRN321) for Patients with Chronic Kidney Disease (CKD) Not on Dialysis in Randomaized Controlled Study ; from the Viewpoint of the Safety. Paper presented at : 2007 ASN Congress (SU-PO818), 2007.

46) Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A : The cardio-renal anaemia syndrome : does it exist? , Nephrol Dial Transplant, 18 (Suppl 8) : viii7-viii12, 2003.

P.51 掲載の参考文献

1) World Health Organization. Nutritional Anaemias : Report of a WHO Scientific Group. Geneva, Switzerland : World Health Organization, 1968.

2) Kazmi, WH, Kausz, AT, Khan, S, et al. Anemia : an early complication of chronic renal insufficiency. Am J Kidney Dis 38 : 803, 2001.

3) 新版日本血液学全書13 付録血液学的正常値. 柴田進, 三輪史朗, 八野昭三編, 血液病学第2版. 丸善, p874-875, 1979.

4) National Kidney Foundation : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 : S1-S145, 2006 (suppl 3).

5) Singh AK, Szczech L, Tang KL, et al. : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006.

6) Drueke TB, Locatelli E CIyne N, et al. : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006.

7) Besarab A, Bolton WK, Browne JK, et al. : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584-590, 1998.

8) Phrommintikul A, Haas SJ, Elsik M, Krum H : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis. Lancet 3 ; 369 (9559) : 381-388, 2007.

9) http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to= http://www.fda.gov/ohrms/dockets/ac/acmenu.htm

10) http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/guide1.htm

11) NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease : Up-date 2000 American Journal of Kidney Diseases 37 (No 1, Suppl 1) : pp S184-S185, 2001.

12) NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease : Up-date 2007 Am J Kidney Dis 50 : 476-530, 2007.

13) 2004年版日本透析医学会「慢性血液透析患者における腎性貧血治療のガイドライン」. 透析会誌 37 (9) : 1737-1763, 2004.

14) Akizawa T, Koshikawa S, lwasaki M : Darbepoetin alfa (KRN321) effectively maintains Hb concentrations at extended intervals relative intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial 11 (3) : 220-226, 2007.

P.61 掲載の参考文献

1) Lysaght MJ. Maintenance dialysis population dynamics : current trends and long-term implication. J Am Soc Nephrol 2002 ; 13 (Suppl 1) : S37-40.

2) 日本透析医学会編. 我が国の慢性透析療法の現況 (2006年12月31日現在), 2007.

3) Keith DS Nichols GA, Gullion CM, Brown JB, Smith DH : Longitudinal follow-up and out-comes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004 ; 164 : 659-663.

4) Sarnak MJ, Levey AS, Schoolwerth AC, et al. : Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 ; 108 : 2154-2169.

5) Silverberg DS, et al. : The cardio-renal anemia syndrome : does it exist? Nephrol Dial Transplant 2003 ; 18 (Suppl. 8) : viii7-viii12.

6) National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39 (Suppl 1) : S1-S266.

7) Imai E, Horio M, Iseki K, et al. : Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007 Jun ; 11 (2) : 156-163.

8) Coresh J, Astor BC, Greene T, et al. : Prevalence of chronic kidney disease and decreased kidney function in the adult US population : Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 Jan ; 41 (1) : 1-12.

9) Astor BC, et al. : Association of kidney function with anemia : The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002 ; 162 : 1401-1408.

10) Kuriyama S, et al. : Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron. 1997 ; 77 (2) : 176-185.

11) Fine LG, et al. : Is there a common mechanisms other than proteinria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000 ; 75 : S22-S26.

12) Nangaku M, et al. : Chronic hypoxia and tubulointerstitial injury : A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006 ; 17 : 17-25.

13) Tsai AG, et al. : Oxygen gradients in the microcirculation. Physiol Rev 2003 ; 83 : 933-963.

14) Manotham K, et al. : Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004 ; 15 : 1277-1288.

15) Adler S, et al. : Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. Am J Soc Nephrol 2002 ; 13 : 1788-1794.

16) Grune T, et al. : Oxidative stress in anemia. Clin Nephrol 2000 ; 53 : S18-S22.

17) Tilman B, et al. : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006 ; 355 : 2071-2084.

18) Ajay K Singh, et al. : Correction of anemia with Epoetin Alfa in chronic kidney disease. N Engl J Med 2006 ; 355 : 2085-2098.

19) Bahlmann et al. : Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004 ; 24 ; 110 (8) : 1006-1012.

20) Bahlmann FH, et al. : Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003 ; 64 (5) : 1648-1652.

21) Mann JFK, et al. : Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int 2004 ; 66 (Suppl 92) : s59-62.

22) K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 ; 43 (Suppl 1) : S1, 1-290.

23) Mojiminiyi OA, Abdella NA, Zaki MY, et al. : Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. Diabet Med. 2006 ; 23 (8) : 839-844.

24) Babazono T, Hanai K, Suzuki K, et al. : Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006 ; 49 (6) : 1387-1393.

25) Parvanova AI, et al. : Insulin resistance and microalbuminuria : Across-sectional, case-control study of 158 patients with type 2 diabetes and different degree of urinary albumin excretion. Diabetes 2006 ; 55 : 1456-1462.

26) FinnDiane Study Group : Diabetic nephropathy in associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003 ; 46 : 1402-1407.

27) Hans I, et al. : Dose albuminuria predict cardiovascular outcomes on treatment with iosartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? : The LIFE study. Diabetes Care 2996 ; 29 : 595-600.

28) Zeeuw D, et al. : Alubuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 ; 110 : 921-927.

29) Mochizuki S, Dahlof B, Shimizu M, et al. : Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study) : a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 ; 28 ; 369 (9571) : 1431-1439.

P.76 掲載の参考文献

1) Joki N, Hase H, Nakamura R, et al. : Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 12 : 718-723, 1997.

2) Ohtake T, Kobayashi S, Moriya H, et al. : High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy : an angiographic examination. J Am Soc Nephrol 16 : 1141-1148, 2005.

3) Hase H, Tsunoda T, Tanaka Y, et al. : Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 70 : 1142-1148, 2006.

4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2006年12月31日現在)

5) 西村眞人 : 血液透析患者における虚血性心筋症の特徴と診断. 心臓 39 : 778-782, 2007.

6) Sosnov J, Lessard D, Goldberg RJ, et al. : Differential symptoms of acute myocardial infarction in patients with kidney disease : a community-wide perspective. Am J Kidney Dis 47 : 378-384, 2006.

7) Nori US, Manoharan A, Thornby JI, et al. : Mortality risk factor in chronic haemodialysis patients with infective endocarditis. Nephrol Dial Transplant 21 : 2184-2190, 2006.

8) Urena P, Malergue MC, Goldfarb B, et al. : Evaluation aortic stenosis in hemodialysis patients : analysis risk factors. Neprologie 20 : 217-225, 1999.

9) 中村敏子, 植田初江 : 血液透析患者における冠動脈疾患の病理. 心臓 39 : 774-777, 2007.

10) Okuno S, Ishimura E, Kitatani K, et al. : Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49 : 417-425, 2007.

11) Block GA, Raggi P, Kooienga L, et al. : Mortality effect of coronary calcification and phosphate binder chice in incident hemodialysis patients. Kidney Int 71 : 438-441, 2007.

12) Brannon ES, Merrill AJ, Warren JV, et al. : The cardiac output in patients with chronic anemia as measured by the technique of right atrial catheterization. J Clin Invest 24 : 332-336, 1945.

13) London GM, Marchais SJ, Guerin AP, et al. : Cardiovascular function in hemodialysis patients. In : Grunfeld Jp, Bach JF, Funck-Brentano JL, Maxwell MH, eds. Advances in Nephrology. Mosby Year Book, St Louis : vol 20 1991.

14) Silverberg DS, Wexler D, Blum M, et al. : Erythropoietin should be part of congestive heart failure management. Kidney Int 64 (Suppl 87) : S40-47, 2003.

15) Cannella G, La Canna G, Sandrini M et al. : Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic uraemic patients. Nephrol Dial Transplant 6 : 31-37, 1991.

16) Fellner SK, Lang RM, Neumann A et al. : Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44 : 1309-1315, 1993.

17) Silverberg DS, Wexler D, Blum M, et al. : The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac calss, and markedly reduces hospitalization. J Am Coll Cardiol 35 : 1737-1744, 2000.

18) Hase H, Immamura Y, Nakamura R, et al. : Effects of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease. JPn Circ J 57 : 131-137, 1993.

19) Foley RN Parfrey PS, Morgan J, et al. : Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 : 1325-1335, 2000.

20) Hayashi T, Suzuki A, Shoji T, et al. : Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure, Am J Kidney Dis 35 : 250-256, 2000.

21) Pisoni RL, Brag9-Gresham JL, Young EW, et al. : Anemia management and outcomes from 12 countries in the Dialysis Outcome and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004.

22) Besarab A, Bolton WK, Browne JK et al. : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584-590, 1998.

23) Singh AK, Szcrech L, Tang KL, et al. : Correction of anemia erythropoietin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006.

24) Tanaka Y, Joki N, Hase H : History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. Nephrol Dial transplant 22 : 2917-2923, 2007.

P.84 掲載の参考文献

1) Fukuhara S, Yamazaki S, Hayashino Y, Green J. Measuring health-related quality of life in patients with end-stage renal disease : why and how. Nat Clin Pract Nephrol 2007 ; 3 (7) : 352-353.

2) 池上直己, 福原俊一, 下妻晃二郎, 池田俊也 : 臨床のためのQOL評価ハンドブック. 医学書院, 東京 : 5 : 2001.

3) Ware JE, Snow KK, Kosinski M, Gandek B, eds. SF-36 Health Survey Mannual and Interpretation Guide. Boston : New England Medical Center 1993.

4) Bergner M, Bobbitt RA, Carter WB, Gilson BS : The Sickness Impact Profile : development and final revision of a health status measure. Med Care 19 (8) : 787-805, 1981.

5) Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3 (5) : 329-338, 1994.

6) Laupacis A, Muirhead N, Keown P, Wong C. A : disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 60 (3) : 302-306, 1992.

7) Tarlov AR, Ware JE, Jr., Greenfield S, Nelson EC, Perrin E, Zubkoff M : The Medical Out-comes Study. An application of methods for monitoring the results of medical care. JAMA 262 (7) : 925-930, 1989.

8) Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K : Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51 (11) : 1037-1044, 1998.

9) Fukuhara S, Ware JE, Jr., Kosinski M, Wada S, Gandek B : Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51 (11) : 1045-1053, 1998.

10) 福原俊一, 鈴鴨よしみ : SF-36v2 京都, 日本語版マニュアル. 健康医療評価研究機構 2004.

11) Fukuhara S, Yamazaki S, Marumo F, Akiba T, Akizawa T, Fujimi S, Haruki S, Kawaguchi Y, Nihei H, Shoji T, Maeda T : Health-related quality of life of predialysis patients with chronic renal failure. Nephron Clin Pract 105 (1) : c1-8, 2007.

12) Green J, Fukuhara S, Shinzato T, Miura Y, Wada S, Hays RD, Tabata R, Otsuka H, Takai I, Maeda K, Kurokawa K : Translation, cultural adaptation, and initial reliability and multitrait testing of the Kidney Disease Quality of Life instrument for use in Japan. Qual Life Res 10 (1) : 93-100, 2001.

13) 三浦靖彦, Green J, 福原俊一 : KDQOL-SF version 1.3 京都, 日本語版マニュアル. 健康医療評価研究機構 2001.

14) Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ. Anemia : an early complication of chronic renal insufficiency. Am J Kidney Dis 38 (4) : 803-812, 2001.

15) Group CES : Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300 (6724) : 573-278, 1990.

16) 秋澤忠男, 福原俊一, 秋葉隆, 丸茂文昭, 黒川清, 杉野信博 : 血液透析患者QOLへのEpoetin alfa (エスポー) 投与の影響に関する検討. 腎と透析 669-676, 2002.

17) Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ : Health-related quality of life among dialysis patients on three continents : the Dialysis Outcomes and Practice Patterns Study. Kidney Int 64 (5) : 1903-1910, 2003.

18) Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, Gillespie BW, Akizawa T, Greenwood RN, Andreucci VE, Akiba T, Held PJ, Port FK : Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res 16 (4) : 545-557, 2007.

19) Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (20) : 2071-2084, 2006.

20) Ritz E, Laville M, Bilous RW, 0'Donoghue D, Scherhag A, Burger U, de Alvaro F : Target level for hemoglobin correction in patients with diabetes and CKD : primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49 (2) : 194-207, 2007.

21) Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (9) : 584-590, 1998.

22) Remuzzi G, Ingelfinger JR. Correction of anemia-payoffs and problems. N Engl J Med 355 (20) : 2144-2146, 2006.

23) Phrommintikul A, Haas SJ, Elsik M, Krum H : Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis. Lancet 369 (9559) : 381-388, 2007.

P.98 掲載の参考文献

1) Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S : European best practice guidelines (EBPG). Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 19 : 1-47, 2004.

2) NKF-KDOQI CPG and CPR 3. 2. Using Iron Agents. Am J Kid Dis 2006 ; 47 : S1-S70.

3) 日本透析医学会エリスロポエチンワーキンググループ 2004年版日本透析医学会「慢性血液透析患者における腎性貧血治療のガイドライン」日本透析医学会誌 37 : 1737-1763, 2004.

4) Pisoni RL, Brag9-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK : Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004.

5) Feder JN, Gnirke A, Thomas W, Tsuchihashi Z. et al. : novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 : 399-408, 1996.

6) Andrews NC Disorders of iron metabolism. N Engl J Med 341 : 1986-1995, 1999.

7) Malyszko J, Mysliwiec M : Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 30 : 15-30, 2007.

8) Ganz T : Molecular control of iron transport. J Am Soc Nephrol. 18 : 394-400, 2007.

9) Ludwiczek S, Aigner E, Theurl I, Weiss G : Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101 : 4148-4154, 2003.

10) Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, Izumi M, Takamitsu Y : Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kid Dis 40 : 1030-1039, 2004.

11) Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, Hasuike Y, Izumi M, Eguchi H, Suzuki K, Nakanishi T : Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol 25 : 2495-2501, 2005.

12) 中西健 : 透析患者における '鉄の囲い込み' 異常 (DIMES症候群) -MIA症候群はDIMES症候群で起こるか-. 日本透析医会雑誌 19 : 468-504, 2004.

13) Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK : The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 : 2654-2657, 1996.

14) Orino K, Lehman L, Tsuji Y, Ayaki H, Torti SV, Torti FM : Ferritin and the response to oxidative stress. Biochem J 357 : 241-247, 2001.

15) Fahmy M, Young SP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines : changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J 296 : 175-181, 1993.

16) Rogers JT, Bridges KR, Durmowicz GP, Glass J, Auron PE, Munro HN : Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 265 : 14572-14578, 1990.

17) Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A : Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65 : 1091-1098, 2004.

18) Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R : Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 20 : 652-655, 1982.

19) Fishbane S, Maesaka JK Iron management in end-stage renal disease. Am J Kidney Dis 29 : 319-333, 1997.

20) Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K Catalytically active iron and bacterial growth in serum of haemodialysis patients after i. v. iron-saccharate administration. Nephrol Dial Transplant 15 : 1827-1834, 2000.

21) Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI : Labile plasma iron in iron overload : redox activity and susceptibility to chelation. Blood 102 : 2670-2677, 2003.

22) 名加富紫生, 岡田裕子, 満田賢二, 他 : ラットにおけるフェリコンおよび3種の静注鉄剤の血漿中消失とクッパー細胞への取込み. 腎と透析 60 : 159-164, 2006.

23) Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G, Danielson BG, Lundqvist H. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using Positron emission tomography. Br J Haematol 2003 ; 120 : 853-859.

24) Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR : Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation : Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 : 975-984, 2007.

25) Attallah N, Osman-Malik Y, Frinak S, Besarab A : Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47 (4) : 644-654, 2006.

P.111 掲載の参考文献

1) 篠田俊雄 : 透析医療事故の全国調査による現況と対策. Clinical Engineering Vol. 15, No. 6, 609-611, 2004.

2) 河野龍太郎 : ヒューマンファクター工学からみた医療システムの安全性. 看護管理 pp. 946-952, Vol. 12, 2002.

3) Reason J : Managing the Risks of Organizational Accident, Ashgate Publishing Limited, 1997. (塩見弘監訳「組織事故」, 日科技連, 1999).

4) 中條武志 : 作業のフールプルーフ化に関する研究. 品質 Vol. 14, No. 2, 1984.

5) 河野龍太郎 : ヒューマンエラー低減技法の発想手順 : エラープルーフの考え方. 日本プラントヒューマンファクター学会誌, Vol. 4, No. 2, pp. 121-130, 1999.

6) 河野龍太郎 : ヒューマンエラー防止への戦略. Emergency Nursing pp. 1-14, Vol. 16, No. 10, 2003.

P.118 掲載の参考文献

1) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況-2006年12月31日現在, (社) 日本透析医学会, 2006.

2) 大平整爾, 菅原剛太郎, 上田峻広, 他 : 北海道における高齢者透析並びに慢性透析患者の終末期医療-その現況と課題-. 日透医誌 19 (2) : 324-346, 2004.

3) 山崎親雄 : 診療報酬改定と今後の透析医療. 日透医誌 21 (3) : 522-535, 2006.

4) Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supple 3) : 14-21, 2001.

5) 平成12年度厚生科学研究補助金, 厚生科学特別研究事業 (主任研究者 : 平澤由平) : 透析医療事故の実態調査と事故対策マニュアルの策定に関する医研究 (研究報告書). 日本透析医誌 16 (2) : 236-263, 2001.

6) 篠田俊雄, 秋澤忠男, 栗原怜, 他 : 「透析医療事故の定義と報告制度」及び「透析医療事故の実態」に関する全国調査について. 透析会誌 36 (8) : 1371-1395, 2003.

7) 管朗, 高松智子, 岸川伸雄, 他 : 血液透析時のエリスロポエチン製剤投与に関わる看護作業時間調査. 看護管理 17 (8) : 685-687, 2007.

8) 河野龍太郎 : エラープルーフの原理. 日本プラントヒューマン・ファクター学会誌 4 (2) : 121-130, 1999.

9) 芝本隆, 阿部薫 : 血液透析スタッフの作業動線から考える透析室とは. 臨床透析 20 (8) : 1063-1068, 2004.

10) 山崎親雄 : 血液透析施設におけるC型肝炎感染事故 (含 : 透析事故) 防止体制の確立に関する研究. 平成14-16年度厚生労働科学研究費補助金肝炎等克服緊急対策事業総合研究報告書. 3 : 2005.

11) 渡邊有三 : 感染性廃棄物の処理. 透析療法のリスクマネジメント (飯田喜俊, 秋澤忠男, 椿原美治編著). 中外医学社, 東京, p256-260, 2002.

P.130 掲載の参考文献

1) Zander, K : Timelines : the maps for managed care. Definition 1 (3) : 1-3, Fall 1986.

2) 中島直樹, 小林邦久, 井口登與志, 他 : 特定健康診査/保険指導時代に対応する日本型Disease Management事業の開発. 医療情報学 27 (1) : 47-55, 2007.

3) 副島秀久 : 医療記録が変わる! 決定版クリニカルパス, 済生会熊本病院パスプロジェクト. p24-32, 医学書院, 東京, 2004.

4) 日本透析医学会 : 慢性血液透析患者における腎性貧血治療のガイドライン. 日本透析会誌 37 : 1737-1763, 2004.

5) NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia of Chronic Kidney Disease in Adults. Am J Kidney Dis 47 : Suppl 3, S16-145, 2006.

6) Revised European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 19 : Suppl 2, ii1-ii47, 2006.

P.139 掲載の参考文献

1) Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tubakihara Y, Imai E, Hori M : Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis, 35 : 250-256, 2000.

2) Hirakata H, Kanai H, Fukuda K, et al. : Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clin Nephrol 53 : 354-361, 2000.

3) Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O : Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondlabetic patients. Nephron 77 : 176, 1997.

4) Field, MJ. and Lohr, K. N. : Clinical Practice Guidelines : Directions for a New Program. National Academy Press, Washington, D. C. 38, 1990.

5) Singh A K, Szczech L, Tang K L, Barnhart H, Sapp S, Wolfson M, Reddan D : CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006.

6) Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE investigators : Normalizaiton of hemoglobin level in patients with chronic kidney disease and anemia., N Engl J Med, 355 : 2071-2084, 2006.

7) NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia in Chronic Kidney Disease : 2007 Update of Hemoglobin Target. Am J Kidney Dis 50 : 471-530, 2007.

8) 日本透析医学会 : 慢性血液透析患者における腎性貧血治療のガイドライン. 透析会誌 37 : 1737-1763, 2004.

9) 平松信, 窪田実, 山本裕康 : 腹膜透析患者に対する腎性貧血治療のガイドラインについて. 日本透析医学会雑誌 40 (Supplement 1) : 290, 2007.

10) 川西秀樹, 久木田和丘, 田熊淑男, 栗原怜, 北岡建樹, 大薗英一, 河野孝史, 中澤了一, 舘野純生, 秋葉隆, 西村民子, 笹岡拓雄, 須賀孝夫, 出浦照國, 鈴木正司, 長嶋悟, 勢納八郎, 越川昭三 : 本邦の血液透析患者におけるrHuEPO製剤休薬後の腎性貧血に対するKRN321 (Darbepoetin alfa) の用量反応試験. 腎と透析 62 (2) : 349-361, 2007.

11) 川西秀樹, 久木田和丘, 田熊淑男, 栗原怜, 北岡建樹, 大薗英一, 河野孝史, 中澤了一, 舘野純生, 秋葉隆, 西村民子, 笹岡拓雄, 須賀孝夫, 出浦照國, 鈴木正司, 長嶋悟, 勢納八郎, 越川昭三 : rHuEPO製剤休薬後腎性貧血に対するKRN321用量反応試験参加血液透析患者を対象とした長期投与試験-KRN321長期投与試験-. 腎と透析 62 (2) : 335-348, 2007.

12) 保利敬, 辻本吉広, 大森浩之, 瀧正史, 中村定敏, 白水明代, 菅朗, 岩崎学, 秋澤忠男, 越川昭三 : KRN321 (Darbepoetin alfa) 第II/III臨床試験-血液透析患者におけるrHuEPO製剤との無作為化二重盲検比較試験-. 腎と透析 62 (3) : 679-691, 2007.

13) 成瀬友彦, 渡邊有三, 石田裕則, 他 : 新規透析導入後rHuEPO製剤未投与の血液透析患者を対象とした貧血改善用量検討試験A07試験-KRN321第III相臨床試験-. 腎と透析 62 (5) : 977-988, 2007.

14) Akizawa T, Koshikawa S, Iwasaki M and the KRN321 A08 study Group : Darbepoetin alfa effectively maintains Hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial 11 (3) : 220-226, 2007.

15) Fukuhara S, Koshikawa S, Iwasaki M, KRN321 A08 Study Group : Quality-of-life improvement in dialysis patients receiving darbepoetin alfa (KRN321). Ther Apher Dial (in press)

16) Hiramatu M, et al. : Darbepoetin alfa (KRN321) administered intravenously once monthly maintains Hb levels in peritoneal dialysis patients. Ther Apher Dial (in press)

17) Kubota M, et al. : Target Level for Hemoglobin Correction by Darbepoetin Alfa (KRN321) for Peritoneal Dialysis (PD) Patients in Japan. Paper presented at : 2007 ASN Congress (SU-PO792) 2007.

18) Hirakata H, Gejyo F, Suzuki M, Saito A, Iino Y, Watanabe Y, Tsubakihara Y, Akizawa T, Koshikawa S : Effect of Darbepoetin Alfa (KRN321) subcutaneous treatment on hemoglobin levels, Health-Related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis. Paper presented at : 2006 ASN Congress (SA-PO204), 2006.

19) Inaguma D, Tsubakihra Y, Hirakata, H Hiroe M, Hada Y, Akizawa T, Koshikawa : Monthly subcutaneous treatment of Darbepoetin Alfa (KRN321) could maintain Higher Hb safety and have benefical effects on cardiac function of Japanese CKD patients not on dialysis. Paper presented at : 44nd ERA-EDTA Congress (SaP353), 2007.

20) Akizawa T, et al. : Taget Level for Hemoglobin Correction by Darbepoetin Alfa (KRN321) for Patients with Chronic Kidney Disease (CKD) Not on Dialysis in Randomaized Controlled Study ; from the Viewpoint of the Efficacy. Paper presented at : 2007 ASN Congress (SU-PO804), 2007.

21) 日本透析医学会統計調委員会 : わが国の慢性透析療法の現況 (2005年12月31日現在). 日本透析医学会, 2006.

22) Ponald L. Pisoni, Jennifer L. Bragg-Gresham, Eric W. Young, Tadao Akizawa, Yasushi Asano, et al. : Anemia Management and Outcomes From 12 Counties in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 : 94-111, 2004.

23) 平松信, 窪田実, 山本裕康 : 腹膜透析患者の目標Hb濃度に対するrHuEPO製剤治療の限界. 腎と透析 63 (6) : 915-922, 2007.

24) 栗山哲, 大塚泰史, 上竹大二郎, 白井泉, 細谷龍雄 : 慢性腎臓病 (CKD) における腎性貧血管理の現況. 日腎会誌 49 (5) : 505-510, 2007.

P.148 掲載の参考文献

1) Cumming DA : Glycosylation of recombinant protein therapeutics : Control and functional implications. Glycobiology 1 : 115-130, 1991.

2) Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, Wiley DC : A carbohydrate side chain on hemagglutinins of hong kong influenza viruses inhibits recognition by a monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America 81 : 1779-1783, 1984.

3) Egrie J, Grant J, Gillies D, Aoki K, Strickland T : The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J10 : 263, 1993.

4) Egrie JC, Browne JK : Development and characterization of novel erythropoiesis stimulating protein (nesp). Nephrol Dial Transplant 16 Suppl 3 : 3-13, 2001.

5) Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J : Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 : 2392-2395, 1999.

6) Macdougall IC obotUNSG : Novel erythropoiesis stimulating Protein (nesp) for the treatment of renal anemia. J Am Soc Nephrol 9 : A258-A259, 1998.

7) Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ : Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rhuepo in dialysis patients. Kidney international 62 : 2167-2175, 2002.

8) Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ : Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 : 110-118, 2002.

9) 保利敬, 辻本吉広, 大森浩之, 瀧正史, 中村定敏, 白水明代, 菅朗, 岩崎学, 秋澤忠男, 越川昭三 : Krn321 (darbepoetin alfa) 第ii/iii相臨床試験血液透析患者におけるrhuepo製剤との無作為化二重盲検比較試験. 腎と透析 62 : 679-691, 2007.

10) Akizawa T, Koshikawa S, Iwasaki M : Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rhuepo in japanese dialysis patients. Ther Apher Dial 11 : 220-226, 2007.

11) Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ : Novel eryth-ropoiesis stimulating Protein for treatment of anemia in chronic renal insufficiency. Kidney international 60 : 741-747, 2001.

12) Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R : Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clinical nephrology 63 : 327-334, 2005.

13) Disney A, Jersey PD, Kirkland G, Mantha M, Charlesworth JA, Gallagher M, Harris D, Gock H, Mangos GJ, Macmillan J, Liu W, Viswalingam A : Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis : A multicentre, open-label, australian study. Nephrology Carlton, Vic 12 : 95-101, 2007.

書評

書評を投稿する

最近チェックした商品履歴

Loading...